



Resonance Health Ltd
ASX / Media Release

5 April 2012

Update on HepaFat Scan™ and Liver Fibrosis Test

The Board of Resonance Health is pleased to provide an update on the status of two important pipeline projects aimed at the development of MRI based technology to measure liver fibrosis and liver fat.

Resonance Health has completed recruitment and MRI scanning of all patients for its study aimed at developing an MRI-based test for liver fibrosis. The Company is currently awaiting results from external laboratories in order to complete the assessment of its MRI technology for measuring liver fibrosis and a further announcement regarding the outcome of this study is anticipated during April.

Resonance Health's HepaFat™ Scan project aims to bring to market an accurate MRI test for the assessment of fatty liver. In December 2011 Resonance Health lodged a Provisional Patent Application for HepaFat™ Scan, a new technology for the MRI measurement of fatty liver. Final testing of the technology is currently underway, ahead of a submission of a 510(K) application to the US Food and Drug Administration. The Company expects to make the submission to the FDA in the current quarter and a response is expected in Q4 2012.

These technologies complement the Company's existing expertise in quantitative liver imaging and the provision of services to pharmaceutical companies developing therapies to address these markets.

By Order of the Board
Resonance Health Limited

For further information please contact:

Resonance Health

Liza Dunne

Managing Director

T: +61 8 9286 5300

E: lizad@resonancehealth.com

Naomi Haydari

Company Secretary

T: +61 8 9286 5300

E: naomih@resonancehealth.com

Resonance Health Ltd (ASX: RHT) (www.resonancehealth.com) is a medical device company providing imaging core laboratory services for the quantitative analysis of medical images, with a subspecialty in the liver. Resonance Health's patented FerriScan technology provides a safe and accurate alternative for measuring liver iron concentration, and research continues into the development of new technology for the accurate assessment of liver fat and liver fibrosis.